Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) (HD2000)

G

Gruppo Italiano Studio Linfomi

Status and phase

Completed
Phase 3

Conditions

Advanced Hodgkin Disease

Treatments

Drug: COPPEBVCAD vs BEACOPP vs ABVD

Study type

Interventional

Funder types

Other

Identifiers

NCT00443677
HD2000

Details and patient eligibility

About

The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.

Enrollment

307 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed diagnosis of Hodgkin disease
  • Clinical stage IIB, III, IV
  • No prior treatment for Hodgkin disease or other malignancy
  • Age 18-65 year
  • Good cardiac, pulmunar, renal and hepatic function
  • Performance status 0-3 (Karnofsky 100- 40)
  • Written Informed Consent

Exclusion criteria

  • HIV positivity
  • Large cell, anaplastic, CD30+ lymphoma

Trial design

307 participants in 3 patient groups

abvd
Active Comparator group
Treatment:
Drug: COPPEBVCAD vs BEACOPP vs ABVD
beacopp
Experimental group
Treatment:
Drug: COPPEBVCAD vs BEACOPP vs ABVD
coppebvcad
Experimental group
Treatment:
Drug: COPPEBVCAD vs BEACOPP vs ABVD

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems